ProMIS Neurosciences shareholders elect all eight directors, ratify auditor, approve continuance

Proposal No. 1 : Election of eight nominees to serve as directors until the 2024 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The votes were cast as follows by holders of Common Shares: ​ ​ ​ ​ Name ​ Votes For ​ Votes Against ​ Abstained Eugene Williams 3,320,369 ​ 147,921 ​ 12,872 Neil Cashman, M.D. 3,470,265 ​ 8,611 ​ 2,286 Gail Farfel, Ph.D. 3,376,107 ​ 103,302 ​ 1,753 Patrick D. Kirwin 3,314,138 ​ 154,640 ​ 12,384 Joshua Mandel-Brehm 3,316,160 ​ 112,636 ​ 52,366 Maggie Shafmaster, Ph.D., JD 3,292,796 ​ 103,924 ​ 84,442 Neil K. Warma 3,266,932 ​ 164,174 ​ 50,056 William Wyman 3,048,981 ​ 382,124 ​ 50.057 ​ ​ Broker Non-Votes: 914,356. All eight nominees were elected.

Proposal No. 3: Approval to continue the Company to the jurisdiction of the Province of Ontario under the Business Corporations Act (Ontario). The votes were cast as follows by holders of Common Shares and Preferred Shares, voting together: ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstained Approval of Continuance into Ontario 4,537,149 ​ 103,948 ​ 6,731 ​ ​ ​ ​

Proposal No. 2: Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows by holders of Common Shares: ​ ​ ​ ​ ​ ​ ​ ​ Votes For Votes Against Abstained Ratification of appointment of Baker Tilly US, LLP 4,294,824 ​ 99,591 ​ 1,103 ​ ​